Project Grant R01AI185516
Award Date 8/19/25
Completion Date 7/31/30
Dollars Obligated $667K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Denmark
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $832,076 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to the University of Massachusetts Medical School (UMMS) to conduct research on protective CD8 T cell responses to tuberculosis (TB). The research aims to characterize how vaccine-elicited CD8 T cells respond to Mycobacterium tuberculosis (MTB) challenge, identify protective antigens recognized by CD8 T cells,...
- This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $429,546 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to National Jewish Health in Colorado. The grant will fund research to evaluate the efficacy of tuberculosis (TB) treatment regimens by analyzing the transcriptomic patterns of Mycobacterium tuberculosis injury and adaptation during drug treatment. The research aims to develop more reliable preclinical measures of TB treatment...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $1,640,492 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Albert Einstein College of Medicine to study the role of the ESX5 secretome of Mycobacterium tuberculosis in TB and TB-HIV pathogenesis and immunity. The researchers generated a genetic deletion of the ESX5 locus, which they found produced a live attenuated vaccine that is highly effective at preventing TB in...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,922,220 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University. The grant supports research to advance apoptosis-inducing agents as host-directed therapy for tuberculosis (TB). The research aims to boost host immune responses via the intrinsic apoptosis pathway to reduce Mycobacterium tuberculosis (MTB) growth and enhance the bactericidal activity of...
- This $2,710,680 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) to develop new generation mRNA-based vaccines for tuberculosis (TB). The goals are to: 1) develop mRNA vaccines expressing protective TB antigens combined with self-adjuvant peptides, 2) characterize the molecular mechanisms of the new mRNA vaccines, and 3) determine the efficacy of the vaccines against TB in mice....
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $750,000 Project Grant to The University of Southern Mississippi to research the role of extracellular polyphosphate in Mycobacterium tuberculosis antibiotic tolerance. The 4-year grant, which begins on Sep 20, 2025 and runs through Aug 31, 2029, aims to investigate the metabolic pathways in M. tuberculosis that regulate extracellular...
- The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,166,933 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Vanderbilt University Medical Center to study Mycobacterium tuberculosis transmission. The project aims to identify bacterial genetic and phenotypic features associated with M. tuberculosis transmission outcomes, including infection, subclinical TB, and clinical TB disease. It will also define M. tuberculosis...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $536,148 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Tufts University School of Medicine to conduct research on integrating point-of-care urine isoniazid testing into routine tuberculosis (TB) care in India. The research aims to facilitate early and accurate identification of TB patients who are at risk of poor outcomes, including death and disease recurrence, due to...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $742,499 Project Grant to the University of Alabama at Birmingham (UAB) for the "Molecular Investigation of Siderophore Secretion and Drug Efflux by Mycobacterium Tuberculosis" research project. This 5-year project, running from August 2025 to July 2030, aims to shed light on the unique siderophore secretion system in Mycobacterium...